1359-6535

Antiviral Therapy

SAGE Publications

View prefix report (10.1177)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 2364 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact2364 DOIs
2

Add abstracts to 271 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact271 DOIs
3

Deposit reference lists for 148 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact148 DOIs

DOIs for this ISSN

Showing the top 5 of 2462 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Host genetics influences on HIV type-1 disease (10.3851/imp1253)
Abstract References ORCID License
136.17 22
2 The course of inactive hepatitis B in hepatitis-C-coinfected… (10.3851/imp1284)
Abstract References ORCID License
117.61 14
3 Mechanisms of HIV and Nucleoside Reverse Transcriptase Inhib… (10.1177/135965350501002s05)
Abstract ORCID
87.79 56
4 Possible Fatal Interaction between Protease Inhibitors and M… (10.1177/135965350000500108)
Abstract ORCID
83.14 45
5 Antiretroviral Activity of Emtricitabine, a Potent Nucleosid… (10.1177/135965350100600201)
Abstract ORCID
76.57 33
6 Nucleoside Reverse Transcriptase Inhibitors, Mitochondrial D… (10.1177/135965350501002s03)
Abstract ORCID
76.57 33
7 Nephrolithiasis in HIV-Infected Patients Treated with Indina… (10.1177/135965359800300207)
Abstract ORCID
69.90 24
8 Silver Nanoparticles Inhibit Hepatitis B virus Replication (10.1177/135965350801300210)
ORCID
67.86 517
9 Selection of K65R Mutation in HIV-2-Infected Patients Receiv… (10.1177/135965350400900422)
Abstract ORCID
63.94 18
10 Abstract (10.1177/135965350200701s01)
Abstract References ORCID
63.38 6
11 Antiretroviral Treatment Failure and HIV-1 Genotypic Resista… (10.1177/135965350200600406)
Abstract ORCID
61.52 16
12 Human Coronaviruses: What Do They Cause? (10.1177/135965350701200s01.1)
ORCID
60.58 264
13 Challenges of Convalescent Plasma Infusion Therapy in Middle… (10.3851/imp3243)
ORCID
60.46 261
14 Article Commentary: ImPortance of IP-10 in Hepatitis B (10.3851/imp3014)
Abstract ORCID
60.21 15
15 The Relation between Baseline HIV Drug Resistance and Respon… (10.1177/135965350000500112)
ORCID
60.08 252
16 Selection of Hepatitis B Virus Polymerase Mutations in HIV-C… (10.1177/135965350501000612)
ORCID
59.04 229
17 Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1… (10.1177/135965350400900115)
ORCID
58.95 227
18 Recommendations for surveillance of transmitted HIV drug res… (10.1177/135965350801302s04)
ORCID
58.41 216
19 Abstracts (10.1177/13596535211063242)
Abstract References ORCID
58.36 5
20 Antiviral Drug Resistance: From the Laboratory to the Patien… (10.1177/135965359800300405)
Abstract References ORCID
58.36 5
21 Abstracts (10.1177/135965359900401s01)
Abstract References ORCID
58.36 5
22 Long-Term Lamivudine Therapy Reduces the Risk of Long-Term C… (10.1177/135965350701200816)
ORCID
58.26 213
23 <i>In vitro</i> Selection and Characteri… (10.1177/135965359900400205)
ORCID
58.16 211
24 Antiretroviral Resistance Testing Comes of Age (10.1177/135965350000500109)
Abstract ORCID
57.31 13
25 Suppression of Hepatitis C Virus Replication is Maintained L… (10.1177/135965350400900116)
Abstract ORCID
57.31 13
26 Increasing Prevalence of HIV-1 Reverse Transcriptase Mutatio… (10.1177/135965350400900519)
Abstract ORCID
57.31 13
27 Management of Antiviral Resistance in Patients with Chronic… (10.1177/135965350400900522)
ORCID
57.31 195
28 TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interac… (10.1177/135965350501000801)
Abstract ORCID
57.31 13
29 Article Commentary: Hepatitis B Antiviral Resistance and Vac… (10.1177/135965350801300314)
Abstract ORCID
57.31 13
30 Article Commentary: HIV Transmission Hunting – the Chase for… (10.1177/135965350801300503)
Abstract ORCID
57.31 13
31 The World Health Organization's global strategy for preventi… (10.1177/135965350801302s03)
ORCID
57.14 192
32 Interruption of Antiretroviral Therapy and Risk of Cardiovas… (10.1177/135965350801300215)
ORCID
56.97 189
33 Lamivudine-Resistant Hepatitis B Virus and Ongoing Lamivudin… (10.1177/135965350400900205)
Abstract ORCID
55.70 12
34 Acute Hypersensitivity with Delavirdine (10.1177/135965359900400107)
Abstract ORCID
55.70 12
35 Hepatitis B surface antigen seroclearance during chronic HBV… (10.3851/imp1497)
ORCID
55.70 168
36 Combination Therapy with Lopinavir/Ritonavir, Ribavirin and… (10.3851/imp3002)
ORCID
55.37 163
37 Prevalence of comedications and effect of potential drug–dru… (10.3851/imp1540)
ORCID
55.30 162
38 Indomethacin Has a Potent Antiviral Activity against Sars Co… (10.1177/135965350601100803)
ORCID
55.10 159
39 Impact of Neuraminidase Mutations Conferring Influenza Resis… (10.1177/135965350601100804)
ORCID
54.69 153
40 <i>In Vitro</i> Susceptibility of Adefov… (10.1177/135965350701200309)
ORCID
54.33 148
41 A Sustained Virological Response to Interferon or Interferon… (10.1177/135965350601100811)
ORCID
54.26 147
42 HIV-1 Infection Leads to Increased HLA-E Expression Resultin… (10.1177/135965350501000107)
ORCID
54.18 146
43 Altered Fat Differentiation and Adipocytokine Expression are… (10.1177/135965350400900412)
ORCID
54.11 145
44 Cross-Resistance Testing of Next-Generation Nucleoside and N… (10.1177/135965350501000507)
ORCID
54.11 145
45 Some HIV Antiretrovirals Increase Oxidative Stress and Alter… (10.1177/135965350701200407)
ORCID
54.03 144
46 Rosiglitazone in the Treatment of Haart-Associated Lipodystr… (10.1177/135965350300800303)
ORCID
53.96 143
47 Uridine Excess does not Interfere with the Antiretroviral Ef… (10.1177/135965350300800516)
Abstract ORCID
53.96 11
48 The Use of Saquinavir/Ritonavir 1000/100 Mg Twice Daily in P… (10.1177/135965350400900606)
Abstract ORCID
53.96 11
49 <i>In Vitro</i> Susceptibility of Adenov… (10.1177/135965350501000204)
ORCID
53.96 143
50 Influenza Virus Susceptibility and Resistance to Oseltamivir (10.1177/135965350701200s04.1)
ORCID
53.81 141